Most Read Articles
6 days ago
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
6 days ago
Use of quetiapine among critically ill patients rarely leads to corrected QT (QTc) interval prolongation, reports a new study.
15 Jun 2018
New drug applications approved by US FDA as of 1 - 15 June 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Pearl Toh, 6 days ago
Drinking more water did not significantly slow down the decline in kidney function of patients with stage 3 chronic kidney disease (CKD) at 1 year compared with patients who maintained their daily water intake, the CKD WIT* randomized study suggests.

Cannabis use ups risk of prescription opioid use disorder

05 Oct 2017

Cannabis use is likely to increase rather than decrease the risk of developing nonmedical prescription opioid use and opioid use disorder, according to a recent study.

Logistic regression models were used to evaluate prospective associations between cannabis use at wave 1 (2001 to 2002) and nonmedical prescription opioid use and prescription opioid use disorder at wave 2 (2004 to 2005) of the National Epidemiologic Survey on Alcohol and Related Conditions. Corresponding analyses were also conducted among adults with moderate or more severe pain and with nonmedical opioid use at wave 1.

Researchers then used a structured interview (the Alcohol Use Disorder and Associated Disabilities Interview Schedule–DSM-IV version) to measure cannabis and prescription opioid use. Other covariates were age, sex, race/ethnicity, anxiety or mood disorders, family history of drug, alcohol, and behavioural problems and nonmedical opioid use in opioid use disorder analyses.

Logistic regression models showed that cannabis use at wave 1 appeared to increase incident nonmedical prescription opioid use (odds ratio [OR], 5.78; 95 percent CI, 4.23 to 7.90) and opioid use disorder (OR, 7.76; 4.95 to 12.16) at wave 2. After adjusting for background characteristics, such associations remained significant (nonmedical opioid use: adjusted OR, 2.62; 1.86 to 3.69; opioid use disorder: adjusted OR, 2.18; 1.14 to 4.14).

Cannabis use among adults with pain at wave 1 correlated with increased incident nonmedical opioid use (adjusted OR, 2.99; 1.63 to 5.47) at wave 2. It also predicted increased incident prescription opioid use disorder, but the association lacked significance (adjusted OR, 2.14; 0.95 to 4.83).

Furthermore, cannabis use among adults with nonmedical opioid use at wave 1 was likely to increase use of nonmedical opioid (adjusted OR, 3.13; 1.19 to 8.23).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
6 days ago
Use of quetiapine among critically ill patients rarely leads to corrected QT (QTc) interval prolongation, reports a new study.
15 Jun 2018
New drug applications approved by US FDA as of 1 - 15 June 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Pearl Toh, 6 days ago
Drinking more water did not significantly slow down the decline in kidney function of patients with stage 3 chronic kidney disease (CKD) at 1 year compared with patients who maintained their daily water intake, the CKD WIT* randomized study suggests.